Roubaix Capital LLC Buys Shares of 73,652 Haemonetics Corporation $HAE

Key Points

• Roubaix Capital LLC invested approximately $4.68 million in Haemonetics Corporation, acquiring 73,652 shares, making it the firm's 16th largest holding.
• Several hedge funds have adjusted their positions in Haemonetics, with institutional investors now owning 99.67% of the company's stock.
• Haemonetics reported earnings of $1.10 per share for the last quarter, exceeding expectations, though revenue fell 4.4% year-on-year.

Roubaix Capital LLC purchased a new position in shares of Haemonetics Corporation (NYSE:HAE - Free Report) in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 73,652 shares of the medical instruments supplier's stock, valued at approximately $4,681,000. Haemonetics accounts for 2.4% of Roubaix Capital LLC's investment portfolio, making the stock its 16th largest holding. Roubaix Capital LLC owned 0.15% of Haemonetics as of its most recent SEC filing.

A number of other large investors have also recently bought and sold shares of HAE. Voya Investment Management LLC increased its stake in Haemonetics by 820.5% in the 4th quarter. Voya Investment Management LLC now owns 316,952 shares of the medical instruments supplier's stock valued at $24,748,000 after buying an additional 282,521 shares during the period. Envestnet Asset Management Inc. increased its stake in Haemonetics by 9.6% in the 4th quarter. Envestnet Asset Management Inc. now owns 48,068 shares of the medical instruments supplier's stock valued at $3,753,000 after buying an additional 4,217 shares during the period. Stifel Financial Corp boosted its holdings in shares of Haemonetics by 7.3% in the fourth quarter. Stifel Financial Corp now owns 14,776 shares of the medical instruments supplier's stock valued at $1,154,000 after acquiring an additional 1,006 shares in the last quarter. The Manufacturers Life Insurance Company boosted its holdings in shares of Haemonetics by 434.8% in the fourth quarter. The Manufacturers Life Insurance Company now owns 314,067 shares of the medical instruments supplier's stock valued at $24,522,000 after acquiring an additional 255,338 shares in the last quarter. Finally, Hood River Capital Management LLC boosted its holdings in shares of Haemonetics by 6.8% in the fourth quarter. Hood River Capital Management LLC now owns 214,290 shares of the medical instruments supplier's stock valued at $16,732,000 after acquiring an additional 13,710 shares in the last quarter. Institutional investors and hedge funds own 99.67% of the company's stock.

Haemonetics Price Performance

Haemonetics stock traded up $2.2060 during midday trading on Friday, reaching $56.1860. The company's stock had a trading volume of 379,814 shares, compared to its average volume of 809,629. Haemonetics Corporation has a fifty-two week low of $50.68 and a fifty-two week high of $94.99. The company has a debt-to-equity ratio of 1.04, a quick ratio of 1.04 and a current ratio of 1.72. The stock's 50 day simple moving average is $69.78 and its 200 day simple moving average is $66.41. The firm has a market capitalization of $2.71 billion, a PE ratio of 17.19, a P/E/G ratio of 1.00 and a beta of 0.40.

Haemonetics (NYSE:HAE - Get Free Report) last released its earnings results on Thursday, August 7th. The medical instruments supplier reported $1.10 EPS for the quarter, beating analysts' consensus estimates of $1.01 by $0.09. The company had revenue of $321.39 million during the quarter, compared to the consensus estimate of $305.12 million. Haemonetics had a return on equity of 26.64% and a net margin of 12.14%.Haemonetics's quarterly revenue was down 4.4% compared to the same quarter last year. During the same quarter last year, the company earned $1.02 earnings per share. Haemonetics has set its FY 2026 guidance at 4.700-5.00 EPS. On average, equities research analysts forecast that Haemonetics Corporation will post 4.55 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several analysts have recently weighed in on the stock. Needham & Company LLC reaffirmed a "buy" rating and issued a $68.00 target price (down previously from $84.00) on shares of Haemonetics in a report on Thursday, August 7th. Barrington Research lowered their target price on shares of Haemonetics from $95.00 to $86.00 and set an "outperform" rating on the stock in a report on Friday, August 8th. Robert W. Baird assumed coverage on shares of Haemonetics in a report on Thursday, June 26th. They issued an "outperform" rating and a $87.00 target price on the stock. Raymond James Financial downgraded shares of Haemonetics from a "strong-buy" rating to an "outperform" rating and lowered their target price for the company from $105.00 to $78.00 in a report on Monday, August 11th. Finally, Citigroup raised Haemonetics from a "neutral" rating to a "buy" rating and set a $90.00 target price for the company in a report on Wednesday, July 9th. One analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average price target of $85.18.

Haemonetics Company Profile

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.